Company profile
Evofem Biosciences, Inc.
OTC: EVFM · Healthcare · Biotechnology
#543 of 1,418 Healthcare companies by revenue48th-percentile growth
EA Score
42DFH 54DQ 27GM 37SS 43
v0.1 · 65/100 weight · provisional
↑ operating margin, return on assets · ↓ growth stability, Altman-Z
Methodology →Revenue TTM
$15.4M
Rev growth YoY (TTM)
-10.8%
Net income (FY)
$391.0k
Employees
29
as of 2026-09-25
Market cap
$1.1M
as of 2026-09-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$20.2M$20.2M2025
Net income$391.0k$391.0k2025
Operating income$3.4M$3.4M2025
Total assets$20.3M$20.3M2025
Liabilities$89.7M$89.7M2025
Equity-$74.3M-$74.3M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY21
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Evofem Biosciences, Inc.’s revenue?
Evofem Biosciences, Inc. booked $20.2M in FY2025 revenue, growing 4.2% year over year — about the middle of the pack among Healthcare companies we track, at a 1.9% net margin.
Peers · Healthcare
Alector, Inc.41DMaxCyte, Inc.48DSCYNEXIS, Inc.61CAcutus Medical, Inc.——Nutrition Management Services Company——Immix Biopharma, Inc.49DNeighbors
San Diego →Key facts
CEOSaundra Pelletier
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeOTC: EVFM
Employees29
IPO date2014-11-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.